~~<i id='026BD753DA'><strike id='026BD753DA'><tt id='026BD753DA'><pre id='026BD753DA'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：entertainment 2025-09-30 06:12:35 Page View：8521

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Medeor's stem cell study, Moderna's stock dip
Next article： Medical records are filled with copy

focus

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Mom launches Girl Scout troop for LGBTQ youth in Texas

2:16AnewGirlScouttroopspecificallyforLGBTQ+youthhaskickedoffintheFortWorth,Texasarea.Here,someofthen

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Novo: Oral version of Ozempic leads to 15% weight loss

LISELOTTESABROE/AFP/GettyImagesAnoralversionofsemaglutide,thedrugmarketedasOzempicandWegovy,ledtodra